Clearside Biomedical Features FDA-Approved XIPERE™ in Multiple Presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings
16. November 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021
11. November 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Third Quarter 2021 Financial Results and Provides Corporate Update
10. November 2021 16:05 ET
|
Clearside Biomedical, Inc.
- XIPERE™ is First FDA-Approved Product for Injection into the Suprachoroidal Space - - Approval-Related Milestones to Provide $19 Million in Non-Dilutive Funding - - Continued Progress in...
Clearside Biomedical to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Wednesday, November 10, 2021
28. Oktober 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) Annual Meeting
13. Oktober 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting
04. Oktober 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
21. September 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India and ASEAN Countries
09. September 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum
23. August 2021 16:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update
10. August 2021 16:05 ET
|
Clearside Biomedical, Inc.
- Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 – - Upcoming FDA PDUFA Action Date in October 2021 for XIPERE™ (triamcinolone acetonide...